Drug intelligence / Profile preview

Hyaprof Soft

Development stage: Unknown
Lead developer: Bioscience Cosmetics
Administration: Intradermal

Overview

Hyaprof Soft is a monodensified, monophasic hyaluronic acid dermal filler developed by BioScience GmbH. It contains a 20 mg/ml concentration of pure hyaluronic acid and is designed for superficial injection to treat fine to medium wrinkles, such as crow's feet and perioral lines, as well as for lip augmentation and periorbital rejuvenation. As a CE-marked medical device, it works by physically replacing lost hyaluronic acid in the dermis to restore facial volume and contour.

Brand names: Hyaprof Soft
Other names: Hyaprof Soft

Beyond the preview

Go deeper on Hyaprof Soft.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyaprof Soft.

Explore the full profile